GlycoMar’s ( cosigned two agreements with U.K.-based firms, Verona Pharma ( and Aquapharm Biodiscovery ( The company will provide Verona Pharma with evaluation of a range of novel anti-inflammatory polysaccharides (NAIPS). Aquapharm Biodiscovery contracted with GlycoMar to utilize its newly available screening services “to progress with the development of our compounds for anti-inflammatory activities for both cosmeceutical and pharmaceutical applications,” explains its CEO, Andrew Mearns Spragg.

Next articleUMMZ Periodical Cicada Page